Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ONC-PluReceptor NK cells
- Development stage
- Phase 2
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ONC-PluReceptor NK cells are an investigational, off-the-shelf cell therapy consisting of natural killer (NK) cells derived from a proprietary induced pluripotent stem cell (iPSC) platform. Developed by Oncternal Therapeutics using their PluReceptor™ technology, these cells are engineered to provide a standardized and scalable source of effector cells for cancer immunotherapy. The PluReceptor platform is designed to enhance the innate anti-tumor activity of NK cells, potentially improving their potency, persistence, and expansion compared to primary NK cells. In clinical development, specifically in collaboration with M.D. Anderson Cancer Center, these cells are being evaluated in combination with the bispecific antibody epcoritamab (targeting CD3 and CD20) and the monoclonal antibody tafasitamab (targeting CD19) for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). This combination strategy leverages the NK cells to perform antibody-dependent cellular cytotoxicity (ADCC) against CD19 and CD20-expressing malignant B-cells.
- Other names
- PluReceptor NK cells
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on ONC-PluReceptor NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ONC-PluReceptor NK cells.